Xilio Therapeutics Announces Updated Phase II Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

Xilio Therapeutics, Inc. announced updated data from its ongoing Phase II clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab in patients with metastatic metastatic microsatellite stable colorectal cancer.